(0.80%) 5 277.51 points
(1.51%) 38 686 points
(-0.01%) 16 735 points
(-0.94%) $77.18
(0.35%) $2.58
(-0.79%) $2 347.70
(-3.10%) $30.56
(0.63%) $1 044.50
(-0.17%) $0.921
(-0.49%) $10.49
(-0.05%) $0.785
(0.15%) $90.40
@ $1.280
发出时间: 13 Feb 2024 @ 22:30
回报率: 171.88%
上一信号: Feb 13 - 03:52
上一信号:
回报率: -3.76 %
Live Chart Being Loaded With Signals
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract...
Stats | |
---|---|
今日成交量 | 564 737 |
平均成交量 | 803 836 |
市值 | 806.31M |
EPS | $0 ( 2024-05-09 ) |
下一个收益日期 | ( $-0.220 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.11 |
ATR14 | $0.0300 (0.86%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-20 | Weber Darin J. | Sell | 17 238 | Class A Ordinary Shares |
2024-03-25 | Control Empresarial De Capitales S.a. De C.v. | Buy | 30 000 | Class A Ordinary Shares (as defined in Exhibit 99.1 hereto) |
2024-03-22 | Control Empresarial De Capitales S.a. De C.v. | Buy | 14 000 | Class A Ordinary Shares (as defined in Exhibit 99.1 hereto) |
2024-03-20 | Control Empresarial De Capitales S.a. De C.v. | Buy | 33 000 | Class A Ordinary Shares (as defined in Exhibit 99.1 hereto) |
2024-03-14 | Control Empresarial De Capitales S.a. De C.v. | Buy | 50 000 | Class A Ordinary Shares (as defined in Exhibit 99.1 hereto) |
INSIDER POWER |
---|
-30.80 |
Last 98 transactions |
Buy: 21 973 373 | Sell: 30 179 737 |
音量 相关性
ProKidney Corp. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
ProKidney Corp. 相关性 - 货币/商品
ProKidney Corp. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-3.17M (0.00 %) |
EPS: | $-0.570 |
FY | 2023 |
营收: | $0 |
毛利润: | $-3.17M (0.00 %) |
EPS: | $-0.570 |
FY | 2022 |
营收: | $0 |
毛利润: | $-3.04M (0.00 %) |
EPS: | $-2.41 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.296 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。